The primary objectives of biostatistics as a core resource in the GI Cancer SPORE are design of studies, ongoing monitoring as needed, producing quality control databases for ongoing studies, and state-of- the-art statistical analyses. The guiding philosophy will be to keep quantitative aspects of the research closely tied to the specific aims, and to have the collaboration of the investigator and biostatistician such that the biologic knowledge of the researcher plays an integral part in shaping the statistical analyses. The resource will be made available to the SPORE projects via a statistician who has knowledge of these key core components. To achieve these objectives, the core biostatistician will be constantly available to SPORE investigators. Discussion of study aims, objectives, appropriate design parameters (i.e. study structure and sample size), the appropriate response to interim analyses, analytical plans and guidance for publication related issues will be provided whenever needed. All analyses will use the most current methods and will be conducted or supervised by the statistician. Because many of these analyses are exploratory and are meant to assess new methods, there will be emphasis on estimation of important clinical and laboratory parameters with confidence intervals and likelihood/Bayesian methodology rather than statistical hypothesis testing. The core statistician has experience in a number of areas of particular value to core investigators; inference in situations where there is relatively little empirical data, analysis of clinical research with small numbers of subjects, gene expression in GI tumors, and evaluation of cancer screening tests.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-03S1
Application #
5209343
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Robinson, Cemre; Estrada, Andrea; Zaheer, Atif et al. (2018) Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. J Clin Endocrinol Metab 103:4293-4303
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Kuboki, Yuko; Fischer, Catherine G; Beleva Guthrie, Violeta et al. (2018) Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol :
Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher L et al. (2018) New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 6:
Hata, Tatsuo; Suenaga, Masaya; Marchionni, Luigi et al. (2018) Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol 188:1723-1733
Noë, Michaël; Rezaee, Neda; Asrani, Kaushal et al. (2018) Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. Am J Pathol 188:1530-1535
Schunke, Kathryn J; Rosati, Lauren M; Zahurak, Marianna et al. (2018) Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 3:42-51
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Staedtke, Verena; Bai, Ren-Yuan; Kim, Kibem et al. (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273-277

Showing the most recent 10 out of 883 publications